Welcome to our dedicated page for Sinovac Biotech news (Ticker: SVA), a resource for investors and traders seeking the latest updates and insights on Sinovac Biotech stock.
Sinovac Biotech Ltd. develops, manufactures and commercializes vaccines and related biological products for human infectious diseases. The China-based biopharmaceutical company’s marketed portfolio includes vaccines for influenza, viral hepatitis, varicella, hand-foot-mouth disease associated with EV71, poliomyelitis, pneumococcal disease and COVID-19, and its pipeline includes combination vaccines, recombinant protein vaccines, mRNA technologies and antibodies.
Company updates commonly address vaccine sales, research and development progress, product approvals, overseas market activity and financial reporting. Recent corporate developments also include Nasdaq listing-compliance matters, auditor engagement, SEC filing status and governance proceedings involving board composition and shareholder-meeting disputes.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced the completion of its third production line for CoronaVac®, enhancing its annual vaccine capacity to 2 billion doses. Over 200 million doses have been delivered to more than 20 countries, with over 100 million administered globally. The production line complies with stringent quality standards and has received emergency use approval from over 30 countries. Sinovac aims to continue expanding production and research for CoronaVac®, contributing to global vaccine availability and affordability.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced an amendment to its shareholder rights plan, extending its expiration date from February 22, 2021, to February 22, 2022. This change is significant as it might influence shareholder protection during potential takeover bids. Sinovac, known for its biopharmaceutical products, is actively involved in creating and marketing various vaccines including those for hepatitis, influenza, and COVID-19. The company is also pursuing international market authorization for its products, which could enhance its growth prospects.
Sinovac Biotech Ltd. (NASDAQ:SVA) announced that the China National Medical Products Administration has granted conditional marketing authorization for CoronaVac, its COVID-19 vaccine for adults. This decision follows extensive submissions and rolling reviews by the NMPA since September 2020. Sinovac has completed over 40 submissions and applied for conditional marketing authorization on February 3, 2021, based on phase III trial data. The approval is pivotal for Sinovac's goal of increasing vaccine availability worldwide as it seeks additional regulatory approvals in multiple countries.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced Phase III results for its COVID-19 vaccine, CoronaVac, following trials in Brazil, Turkey, Indonesia, and Chile. The trials enrolled 25,000 participants, showing an efficacy rate of 50.65% for all cases and 83.70% for cases requiring medical treatment. In Turkey’s second trial stage, the efficacy rate was 91.25% after vaccination. Sinovac has filed for conditional market authorization with China’s NMPA and is actively pursuing regulatory approval in additional countries to enhance global vaccine accessibility.
Sinovac Biotech Ltd. (NASDAQ: SVA) has filed for conditional market authorization for its COVID-19 vaccine, CoronaVac, with China's National Medical Products Administration (NMPA). Preliminary results from phase III clinical studies indicate a favorable safety profile for the vaccine, achieving efficacy standards set by the World Health Organization and NMPA. Sinovac anticipates this authorization will enhance its market presence and facilitate international growth in the biopharmaceutical sector.
Sinovac Biotech Ltd. (NASDAQ:SVA) has received regulatory approval from the China National Medical Products Administration for its 23-Valent Pneumococcal Polysaccharide vaccine. This vaccine aims to prevent infections caused by Streptococcus pneumoniae in adults and children aged two and above. Initiated in 2009, the vaccine's development was completed through multiple phases, including a Phase III study that demonstrated its safety and effectiveness. This approval marks a significant milestone as Sinovac's first bacterial vaccine, enhancing its product portfolio.
Sinovac Biotech Ltd. (NASDAQ: SVA) reports strong financial results for Q3 2020, with sales soaring to $115.5 million, a 79.4% year-over-year increase. Net income attributable to common shareholders rose to $9.6 million, or $0.10 per share, compared to $6.3 million last year. However, net loss for the nine months ending September 30 was $3.0 million due to increased R&D expenses. The company also reported progress in COVID-19 vaccine trials and partnerships to enhance its research and development pipeline. Cash and equivalents stand at $150.2 million, supporting operations for at least 12 months.
Sinovac Biotech Ltd. (NASDAQ: SVA) announced that its subsidiary, Sinovac Life Sciences Co., Ltd., secured approximately $500 million in funding from Sino Biopharmaceutical Limited. This investment grants Sino Biopharmaceutical approximately 15% equity interest in Sinovac LS and aims to enhance the development and manufacturing capabilities for the COVID-19 vaccine, CoronaVac. With ongoing Phase III trials approved in several countries, Sinovac anticipates annual production capacity of 600 million doses after expansion. The funding is expected to accelerate Sinovac's efforts against the pandemic.
Sinovac Biotech Ltd. (NASDAQ:SVA) announced that the Beijing Fourth Intermediate Court found Sinobioway Medicine and Mr. Aihua Pan liable for torts and breaches of fiduciary duty. The court ruling stemmed from a 2018 complaint by Sinovac Hong Kong concerning an attempt to take control of Sinovac’s facility, which led to product destruction valued at RMB15.404 million. The ruling allows for an appeal within 15 days by the defendants or 30 days by the plaintiff. Sinovac continues to focus on developing and selling vaccines in China and internationally.